News APP

NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  gplay

This article was first published 1 year ago
Rediff.com  » News » Good Samaritan donates Rs 15.31 cr for child's life-saving drug

Good Samaritan donates Rs 15.31 cr for child's life-saving drug

Source: PTI
February 23, 2023 15:37 IST
Get Rediff News in your Inbox:

A couple from Mumbai who recently shifted to Kerala has received Rs 15.31 crore from an anonymous donor to purchase a life-saving drug for the treatment of their 16-month-old son.

IMAGE: Kindly note that this image has been posted for representational purposes only. Photograph: Kind courtesy Vegasjon/Wikimedia Commons

Marine engineer Sarang Menon and and Adithi Nair's son Nirvaan was diagnosed with spinal muscular atrophy (SMA) type 2, a rare disease for which a key one-time drug costs almost Rs 17.3 crore.

Donations began pouring in after a crowdfunding page was started on Milaap.org, but the identity of the person who gave USD 1.4 million, or Rs 15.31 crore, is unknown, Nair told PTI.

 

The target set by Menon when the crowdfunding page began was Rs 17.50 crore.

"We are happy this contribution has taken us very close to our target. I think we will manage to raise the remaining amount on our own as well as through relatives and friends," she said.

"However, it will take at least 2-3 weeks for us to take Nirvaan back to Mumbai due to some mandatory testing and the time required for the arrival of the drug from the US to Mumbai," Nair informed.

The family has already initiated required communication with the Union finance ministry and import-export department for necessary clearances for the drug.

Dr Neelu Desai, paediatric neurologist at Hinduja Hospital will be treating Nirvaan.

SMA is a group of ailments in which specialised nerve cells in the brain and spinal cord, also called motor neurons, that control movement in the arms, legs, face, throat, tongue get killed.

Get Rediff News in your Inbox:
Source: PTI© Copyright 2024 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.